Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England-Reference-Cited by-同舟云学术

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England

Published:2021-07-15 Issue:28 Volume:26 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Powell Annabel A¹,Power Linda¹,Westrop Samantha¹,McOwat Kelsey¹,Campbell Helen¹,Simmons Ruth¹,Ramsay Mary E²¹,Brown Kevin¹,Ladhani Shamez N³¹,Amirthalingam Gayatri¹

Affiliation:

1. Immunisation and Countermeasures Division, Public Health England, London, United Kingdom

2. London School of Hygiene and Tropical Medicine, London, United Kingdom

3. Paediatric Infectious Diseases Research Group, St. George’s University of London, London, United Kingdom

Abstract

Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among ≤ 50 than > 50 year-olds, women and those with prior symptomatic/confirmed COVID-19. Adults receiving heterologous schedules on clinical advice after severe first-dose reactions had lower reactogenicity after dose 2 following Vaxzevria/Comirnaty (93.4%; 95% confidence interval: 90.5–98.1 vs 48% (41.0–57.7) but not Comirnaty/Vaxzevria (91.7%; (77.5–98.2 vs 75.0% (57.8–87.9).

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference16 articles.

1. Swedish Public Health Agency. Recommendation for a 65-year age limit for AstraZeneca's vaccine remains. [Swedish]. Stockholm: Folkhälsomyndigheten; 2021. Available from: https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2021/april/rekommendation-om-aldersgrans-pa-65-ar-for-astrazenecas-vaccin-kvarstar/

2. Haute Autorité de Santé. Covid-19: what vaccine strategy for people under 55 who have already received a dose of AstraZeneca? [French]. Saint-Denis: Haute Autorité de Santé; 2021. Available from: https://www.has-sante.fr/jcms/p_3260335/

3. Danish Health Authority. Denmark continues its vaccine rollout without the COVID-19 vaccine from AstraZeneca. Copenhagen: Danish Health Authority; 2021. Available from: https://www.sst.dk/en/English/news/2021/Denmark-continues-its-vaccine-rollout-without-the-COVID-19-vaccine-from-AstraZeneca

4. Public Health Agency of Canada. NACI rapid response: Interchangeability of authorized COVID-19 vaccines. Ottawa: Public Health Agency of Canada; 2021. Available from: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/rapid-response-interchangeability.html

5. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.;Shaw;Lancet,2021

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review for the prevention and management of Helicobacter pylori induced gastritis through development of novel vaccine candidates;The Microbe;2024-09

2. Incorporating face-to-face and online learning features to propose blended learning framework for Post-COVID classrooms in India;Asian Association of Open Universities Journal;2024-06-25

3. Development of quality assessment tool for systematic reviews and meta-analyses of real-world studies: a Delphi consensus survey;Rheumatology International;2024-04-29

4. Data and Evidence of Real Clinical Practice: A Comparative Legal Study;Actual Problems of Russian Law;2024-02-16

5. Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women;Human Vaccines & Immunotherapeutics;2023-07-13